During last month´s WIN – Worldwide Innovative Networking in personalized cancer medicine, Symposium, June 29 – 30, Paris, France, ecancer caught up with Paolo Nuciforo, Principal Investigator of VHIO´s Molecular Oncology Group, for his reflections on taking biopsies in clinical trials: the WINTHER laboratory experience, as well as the importance of target expression in personalised medicine.
To view both interviews, please click on the links below.
Paolo Nuciforo on the importance of target expression in personalised medicine:
http://ecancer.org/video/3842/the-importance-of-target-expression-in-personalised-medicine.php
Paolo discusses the unique approach of taking dual biopsies of tumour and normal tissue from patients in the WINTHER trial:
For more information surrounding VHIO´s involvement in the WIN Consortium as well as its participation in the WINTHER (WINTherapeutics) international clinical trial, contact: Amanda Wren, Director of Communication, the Vall d´Hebron Institute of Oncology (VHIO), Email: awren@vhio.net, Tel.: +34 695207886.
